EUVIMEDEUVIMED entdecken
Open Access

Interferon-gamma release assay positivity in populations at high risk of TB infection

A F Dagnew, L L Han, A Cinar, D Gaikwad, A L Garcia-Basteiro, M T Gler, S R Hadinegoro, W A Hanekom, J R Lama, M Muyoyeta, S Musala, V Nduba und 11 weitere

IJTLD Open · 2026-04 · 3 (4) · 232-240

DOI: 10.5588/ijtldopen.25.0684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJTLD Open, online erschienen am 01.04.2026. Verfasst von A F Dagnew und 22 weiteren Autor:innen. Beteiligte Einrichtung: Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Phase 3 TB vaccine trials are challenging in low-incidence settings due to the need for large sample sizes and extended follow-up. This global, observational study evaluated population-based interferon-gamma release assay (IGRA) status – a measure of TB infection (TBI), as a proxy for TB incidence to identify trial sites in high-incidence areas. METHODS Participants (15–34 years) were recruited from 45 sites in 14 countries. IGRA status at Day 1 and Month 12, association of IGRA status with age, and IGRA conversion (TBI) were assessed. RESULTS Among 7,164 enrolled participants, Day 1 IGRA positivity varied across sites and within countries, with the highest prevalence observed in South Africa (58.7%, site 1006; 53.1%, site 1010; 51.9%, site 1007) and the Democratic Republic of Congo (50.0%, site 2303). IGRA positivity was generally higher among older participants. At Month 12, sites with highest IGRA conversion were observed in the Philippines (32.3%, site 1507) and Zambia (30.6%, site 1303). CONCLUSION In TB vaccine efficacy trials with clinical endpoints, selecting sites with the highest TB incidence is critical to optimise sample size and follow-up duration. Site-level IGRA status could inform site selection by identifying communities at increased risk of Mycobacterium tuberculosis infection.

Schlagwörter

Stichwörter der Autor:innen

IGRATBIepidemiologytuberculosisvaccine efficacy trial

Autor:innen und Institutionen

  • Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA.
  • Department of Pulmonary Medicine, PCMC'S PGI YCM Hospital, Pune, India.
  • Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
  • Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.
  • TB HIV Innovations and Clinical Research Foundation, Cavite, Philippines.

Zitieren

APA

Dagnew, A. F., Han, L. L., Cinar, A., Gaikwad, D., Garcia-Basteiro, A. L., Gler, M. T., Hadinegoro, S. R., Hanekom, W. A., Lama, J. R., Muyoyeta, M., Musala, S., Nduba, V., Rolla, V. C., Roy, T., Sutherland, J. S., Viegas, S., Wajja, A., Walker, T. M., Noble, R., …, & TBV02-E01 Study Group (2026). Interferon-gamma release assay positivity in populations at high risk of TB infection. IJTLD Open, 3(4), 232-240. https://doi.org/10.5588/ijtldopen.25.0684

Vancouver

Dagnew AF, Han LL, Cinar A, Gaikwad D, Garcia-Basteiro AL, Gler MT, et al. Interferon-gamma release assay positivity in populations at high risk of TB infection. IJTLD Open. 2026;3(4):232-240. doi:10.5588/ijtldopen.25.0684

BibTeX
@article{Dagnew2026,
  author = {Dagnew, A F and Han, L L and Cinar, A and Gaikwad, D and Garcia-Basteiro, A L and Gler, M T and Hadinegoro, S R and Hanekom, W A and Lama, J R and Muyoyeta, M and Musala, S and Nduba, V and Rolla, V C and Roy, T and Sutherland, J S and Viegas, S and Wajja, A and Walker, T M and Noble, R and Schlehuber, L and Sunshine, J and Schmidt, A C and TBV02-E01 Study Group, TBV02-E01 Study Group},
  title = {Interferon-gamma release assay positivity in populations at high risk of TB infection},
  journal = {IJTLD Open},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {232--240},
  doi = {10.5588/ijtldopen.25.0684}
}
Kostenlos starten →